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Abstract
Background: Chronic Fatigue Syndrome (CFS) is a common and disabling condition in adolescence with few
treatment options. A central feature of CFS is orthostatic intolerance and abnormal autonomic cardiovascular
control characterized by sympathetic predominance. We hypothesized that symptoms as well as the underlying
pathophysiology might improve by treatment with the alpha2A–adrenoceptor agonist clonidine.
Methods: A total of 176 adolescent CFS patients (12–18 years) were assessed for eligibility at a single referral center
recruiting nation-wide. Patients were randomized 1:1 by a computer system and started treatment with clonidine
capsules (25 μg or 50 μg twice daily, respectively, for body weight below/above 35 kg) or placebo capsules for
9 weeks. Double-blinding was provided. Data were collected from March 2010 until October 2012 as part of The
Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial
(NorCAPITAL). Effect of clonidine intervention was assessed by general linear models in intention-to-treat analyses,
including baseline values as covariates in the model.
Results: A total of 120 patients (clonidine group n = 60, placebo group n = 60) were enrolled and started treatment.
There were 14 drop-outs (5 in the clonidine group, 9 in the placebo group) during the intervention period. At 8 weeks,
the clonidine group had lower plasma norepinephrine (difference = 205 pmol/L, p = 0.05) and urine norepinephrine/
creatinine ratio (difference = 3.9 nmol/mmol, p = 0.002). During supine rest, the clonidine group had higher heart rate
variability in the low-frequency range (LF-HRV, absolute units) (ratio = 1.4, p = 0.007) as well as higher standard deviation
of all RR-intervals (SDNN) (difference = 12.0 ms, p = 0.05); during 20° head-up tilt there were no statistical differences in
any cardiovascular variable. Symptoms of orthostatic intolerance did not change during the intervention period.
Conclusions: Low-dose clonidine reduces catecholamine levels in adolescent CFS, but the effects on autonomic
cardiovascular control are sparse. Clonidine does not improve symptoms of orthostatic intolerance.
Trial registration: Clinical Trials ID: NCT01040429, date of registration 12/28/2009.
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Background
Chronic Fatigue Syndrome (CFS) is a disabling condition
with unknown pathophysiology. In adolescents, preva-
lence has been estimated from 0.1 to 2.4 % depending
on definition of CFS and method of estimation [1, 2].
Apart from a single trial of intravenous immunoglobulin
in adolescents with CFS [3], no pharmacotherapy has
proven beneficial in this patient population.
Orthostatic intolerance is common with a prevalence
of more than 25 % in adults with CFS [4], and more than
90 % in children with CFS [5, 6]. Previously, dysregula-
tion of autonomic cardiovascular control has been dem-
onstrated in adults as well as adolescents, characterized by
increased sympathetic and decreased parasympathetic
nervous activity [7–10]. This autonomic imbalance might
reflect alteration of central control mechanism [11, 12],
and provide a target for pharmacotherapy [7, 13].
Clonidine is a centrally acting agonist to the pre-
synaptic alpha2A receptor, thereby attenuating sympa-
thetic nervous activity and enhancing parasympathetic
activity, even in low doses [14–16]. Thus, clonidine
has well-known antihypertensive properties. A pilot study
suggested normalization of cardiovascular variables in
adolescent CFS patients receiving low-dose clonidine [17].
However, a single nucleotide polymorphism (SNP) of the
alpha2A receptor gene might possible modify the effect of
clonidine treatment [18].
The aim of this study was to investigate the effects
of low-dose clonidine on autonomic cardiovascular
control in adolescent CFS. We hypothesized that clo-
nidine would improve symptoms of orthostatic in-
tolerance and normalize cardiovascular variables and
indices of autonomic nervous activity at rest as well
as during orthostatic challenges. The study is part of
the NorCAPITAL-project (The Norwegian Study of
Chronic Fatigue Syndrome in Adolescents: Patho-
physiology and Intervention Trial; ClinicalTrials ID:
NCT01040429, date of registration 12/28/2009).
Methods
Patients
All hospital pediatric departments in Norway (n = 20) as
well as primary care pediatricians and general practi-
tioners were invited to refer patients aged 12 – 18 years
to the national referral center for young CFS patients at
Oslo University Hospital. The referring units were
equipped with written information for distribution to po-
tential study participants and their parents/next-of-kin. If
consent was given, a standard form required the referral
unit to confirm the result of clinical investigations consid-
ered compulsory to diagnose pediatric CFS according to
national Norwegian recommendations (pediatric specialist
assessment, comprehensive hematology and biochemistry
analyses, chest x-ray, abdominal ultrasound, and brain
magnetic resonance imaging). Also, the referring units
were required to confirm that the patient a) was unable to
follow normal school routines due to fatigue; b) was not
permanently bedridden; c) did not have any concurrent
medical or psychiatric disorder that might explain the fa-
tigue; d) did not experience any concurrent demanding
life event (such as parents’ divorce) that might explain the
fatigue; e) did not use prescribed pharmaceuticals (includ-
ing hormone contraceptives) regularly. A previous de-
manding life event was not an exclusion criterion.
Completed forms were consecutively conveyed to the
study center and carefully evaluated by either of two au-
thors (DS or EF). Patients considered eligible to this study
were invited to a clinical encounter at our study center
after which a final decision on inclusion was made.
In agreement with clinical guidelines [19, 20], this study
applied a “broad” case definition of CFS, requiring three
months of unexplained, disabling chronic/relapsing fatigue
of new onset. We did not require that patients meet any
other accompanying symptom criteria. Details of inclusion
and exclusion criteria are provided in Table 1.
Study design
All included patients underwent a baseline investigational
program at our research unit. Thereafter, they were ran-
domized to 9 weeks of treatment with oral clonidine
capsules or placebo capsules in a 1:1 ratio, using a
computer-based routine for stratified randomization
(block size: 4); 18 months disease duration (the median dis-
ease duration in a previous follow-up study [21]) served as
the stratification criterion. Because of practical issues,
randomization was performed prior to final decision on en-
rolment; the procedure was carried out by a research nurse
not otherwise affiliated with the study. Outcome was
assessed by an investigational program identical to the
baseline program at week 8 and week 30; in this article,
only results from week 8 are reported. Patients and re-
searchers were blinded to treatment allocation at all stages.
Clonidine dosages were 50 μg B.I.D for body
weight >35 kg, and 25 μg B.I.D for body weight <
35 kg. Catapresan® 25 μg clonidine hydrochloride tab-
lets (Boehringer Ingelheim, Germany) were enclosed in
orange opaque, demolition-restraint lactose capsules
(Apoteket Produktion & Laboratorier, Kungens Kurva,
Sweden). Identical capsules without Catapresan® were
used as placebo comparator. Half the dose was given for
the first 3 days of the intervention period in order to
minimize adverse introductory effects. Blood samples for
clonidine concentration analyses were taken approxi-
mately two weeks after start of the intervention, and at
the second visit.
NorCAPITAL was approved by the Norwegian Na-
tional Committee for Ethics in Medical Research and
the Norwegian Medicines Agency. Data were collected
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in the period March 2010 until October 2012. Written
informed consent was obtained from all participants,
and from parents/next-of-kin if required.
Investigational program
A one-day in-hospital assessment included clinical
examination, blood sampling (antecubital venous punc-
ture), and 20° head-up tilt test (HUT), and always com-
menced between 7.30 and 9.30 a.m. Patients were
instructed to fast overnight and abstain from tobacco
products and caffeine for at least 48 h, to bring a morn-
ing spot urine sample in a sterile container, and to apply
the local anesthetic lidocaine (Emla®) on the skin in the
antecubital area one hour in advance. At week 8, CFS
patients were told to postpone their prescribed morning
study drug dose (clonidine/placebo) until after blood
sampling and HUT. All procedures were undertaken in
a quiet, warm room in a fixed sequence and by three re-
searchers only (DS, EF and AW). Blood samples were
obtained in a fixed sequence from antecubital venous
puncture after at least five minutes supine rest in calm
surroundings. Samples of oral mucosa were collected for
genetic analyses. Following the in-hospital assessment, a
self-administered questionnaire was completed.
Laboratory analyses
The blood samples for plasma norepinephrine (NA) and
epinephrine (A) analyses were obtained in vacutainer
tubes treated with ethylene glycol tetraacetic acid
(EGTA)–Glutathione. The samples were placed on ice for
approximately 30 min; thereafter, plasma was separated by
centrifugation (3000 rpm, 15 min, 4 °C) and frozen at –
80 °C until assayed. Samples were analyzed for plasma NA
and A by high-performance liquid chromatography
(HPLC) with a reversed-phase column and glassy carbon
electrochemical detector (Antec, Leyden Deacade II SCC,
Zoeterwoude, The Netherlands) using a commercial kit
(Chromsystems, München, Germany) [22–24]. All sam-
ples were measured in singlet, with serial samples from a
given individual run at the same time to minimize run-to-
run variability. The intra- and interassay coefficient of
variation (CV) were 3.9 and 10.8 %, respectively. The de-
tection limit was 5.46 pM.
Urine samples for NA and A analyses were collected
in 10 ml universal containers. Immediately after collec-
tion the urine was acidified to pH ≈ 2.5, thereafter, stored
at 2–8 °C until assayed. Urine treated this way is stable
at least 5 days. The analyses were performed consecu-
tively. The same HPLC protocol as for plasma measure-
ment was used for the measurement of urin NA/A. The
intra- and interassay coefficient of variation (CV) for
urine were 3.9 and 5.2 %, respectively.
The blood samples for clonidine determinations were
collected in 4 mL heparin tubes. After centrifugation for
12 min at 1000 g at room temperature, the plasma
fraction was frozen at −20 °C until analysis. A slight
Table 1 Criteria for inclusion and exclusion
Inclusion criteria Exclusion criteria
CFS patients Persisting or constantly relapsing fatigue lasting
3 months or more.
Another current disease process or demanding life event
that might explain the fatigue
Functional disability resulting from fatigue to a
degree that prevent normal school attendance
Another chronic disease





Evidence of reduced cerebral and/or peripheral circulation
due to vessel disease
Polyneuropathy
Renal insufficiency
Known hypersensitivity towards clonidine or inert substances
(lactose, saccarose) in capsule
Abnormal ECG (apart from ectopic beats)
Supine heart rate < 50 beats/min
Supine systolic blood pressure < 85 mmHg
Upright systolic blood pressure fall > 30 mmHg
Healthy control subjects Age≥ 12 years and < 18 years Another chronic disease
Permanent use of drugs (including hormones)
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modification of the method described by Müller et al.
[25] was used for plasma clonidine assaying. The assay
was validated based on FDA guidelines [26]. The sam-
ples were separated on an Alliance HT 2795 HPLC
system and detected by a Micromass Quattro micro
API MS/MS-instrument. System control, data acquisi-
tion and integration were performed by Masslynx
software Ver 4.1.2008 (all from Waters, Milford, MA,
USA). The MS/MS conditions were optimized by
manual tuning during pump-infusion of neat solu-
tions. The assay was set up to quantify from 0.10 μg/
L to 5.00 μg/L clonidine in plasma. Quality control
samples were included in all sample series, and placed
both before and after the patient samples in each
analytical run. The median intra assay CV was 1 % at
5 μg/L, 5 % at 0.75 μg/L and 10 % at 0.10 μg/L. The
inter assay CV was 6 % at 5 μg/L, 5 % at 0.75 μg/L
and 12 % at 0.10 μg/L. Limit of detection, defined as
a peak-to-peak signal to noise ratio of 5:1, verified by
the Masslynx software, was 0.025 μg/L. Accuracy was
97 % (median) at 5 μg/L, 97 % at 0.75 μg/L, and
107 % at 0.10 μg/L.
The genotyping of the alpha2A receptor single nucleo-
tide polymorphism (SNP) rs1800544 was carried out by
predesigned TaqMan SNP genotyping assay (Applied
Biosystems, Foster City, CA, USA), using the SDS 2.2
software (Applied Biosystems). As previously described,
approximately 10 % of the samples were re-genotyped,
and the concordance rate was 100 % [27]. Genotyping
was also performed in 68 healthy individuals having the
same distribution of gender and age as the CFS patients.
Head-up tilt-test
Head-up tilt-test (HUT) was performed using an elec-
tronically operated tilt table with foot-board support
(Model 900–00, CNSystems Medizintechnik, Graz,
Austria). Patients were connected to the Task Force Moni-
tor (TFM) (Model 3040i, CNSystems Medizintechnik,
Graz, Austria), a combined hardware and software device
for noninvasive recording of cardiovascular variables.
5 min was used for supine recordings, after which the par-
ticipants were head-up tilted to 20° for 15 min. Details of
the HUT protocol have been described elsewhere [9]. The
feasibility of this protocol for studying adolescent CFS pa-
tients has been demonstrated in several previous studies
[9, 28]. In particular, the low tilt angle (20°) does not nor-
mally precipitate syncope, which is otherwise a common
problem among adolescents being subjected to stronger
orthostatic challenges [29]. Still, 20° head-up tilt is suffi-
cient to demonstrate hemodynamic alterations and com-
pensatory autonomic responses.
Instantaneous RR intervals (RRI) and heart rate (HR)
were obtained from the electrocardiogram (ECG). Con-
tinuous arterial blood pressure was obtained noninvasively
using photoplethysmography on the right middle finger.
Mean arterial blood pressure (BP) was calculated by nu-
merical integration of the recorded instantaneous BP.
The recorded value was calibrated against conventional
oscillometric measurements of arterial BP on the left
arm every five minutes according to the TFM manufac-
turer’s recommendation. Impedance cardiography with
electrodes placed on the neck and upper abdomen was
used to obtain a continuous recording of the temporal
derivative of the transthoracic impedance (dZ/dt). Beat-
to-beat stroke volume was calculated from the imped-
ance signal [30].
Power spectral analysis (frequency-domain method) of
HR variability and systolic blood pressure (SBP) variabil-
ity was automatically provided by the TFM, using an
adaptive autoregressive model [31]. Power was calcu-
lated in the Low Frequency (LF) range (0.05 to 0.17 Hz),
and High Frequency (HF) range (0.17 to 0.4 Hz). In
addition, time-domain indices of variability were com-
puted from the RRIs: The standard deviation of all RR-
intervals (SDNN), the proportion of successive RRIs with
a difference greater than 50 ms (pNN50), and the square
root of the mean square differences of successive RRIs
(r-MSSD).
Heart rate variability (HRV) is considered an index of
autonomic cardiac modulation. In the frequency-domain,
vagal (parasympathetic) activity is the main contributor to
HF variability, whereas both vagal and sympathetic activity
contributes to LF variability [32]. The LF/HF ratio is con-
sidered an index of sympathovagal balance. SBP variability
is regarded an index of sympathetic modulation of periph-
eral resistance vessels [33]. For time-domain indices, vagal
(parasympathetic) activity is the main contributor to
pNN50 and r-MSSD, whereas SDNN is a measure of total
variability, analogous to the Total Power index in the fre-
quency domain.
Data from each HUT procedure was exported to
Microsoft Excel for further calculations. Beat-to-beat
stroke index (SI) was calculated dividing stroke volume
by body surface area, and beat-to-beat total peripheral
resistance index (TPRI) was calculated as mean BP di-
vided by the product of SI and HR. For each participant,
the following epochs of the recordings were chosen:
Baseline (270 to 30 s before tilt up) and Early tilt (30 to
270 s after tilt). In each epoch we computed the median
value for the conventional cardiovascular variables as
well as the indices of HR and SBP variability; this pro-
cedure reduces the influence of erroneous outliers, such
as ectopic heart beats. Thereafter, the delta values (Early
Tilt – Baseline) which are considered indices of the car-
diovascular response to orthostatic challenge were com-
puted for each participant. This analytic approach has
been proven feasible in several previous report from our
group [9–11].
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Questionnaire
The participants received a comprehensive questionnaire
consisting of several validated inventories, as has been
described in detail elsewhere [28].
The Autonomic Symptom Profile (ASP) [34], which
has been used in previous Norwegian CFS studies but
which is not validated for the Norwegian language, was
slightly modified in order to fit our age group. A com-
posite score reflecting orthostatic symptoms was con-
structed from 8 single items from the ASP, addressing
experiences of dizziness in specific situations (such as
rising suddenly from supine position, taking a shower,
etc.). The total sum score is from 0 to 8; higher values re-
flect more pronounced orthostatic problems. In addition,
other symptoms related to autonomic cardiovascular con-
trol, such as palpitations and pale and cold hands, were
charted on a 1–5 Likert scale.
The questionnaire also included the CFS symptom in-
ventory for adolescents [28, 35]. This inventory was used
to subgroup the CFS patients according to the 1994 CFS
case definition [36].
Statistics
Determination of sample size is described elsewhere
[28]. Outcome of clonidine intervention was assessed by
general linear models (ANCOVA) in intention-to-treat
analyses, including baseline values as covariates in the
model [37]. The net intervention effect was calculated
from the parameters of the fitted general linear model.
Differential effects in subgroups adhering to the 1994
CFS case definition, genotype of the alpha2A receptor
single nucleotide polymorphism (SNP) rs1800544, and
sex, were explored by including these variables as inter-
action terms. Dose–response relationships for patients
allocated to clonidine were explored by linear regres-
sion analyses. Missing values were imputed as last ob-
servation carried forward from the pre-medication
test. In order to obtain near-normally distributed vari-
ables, ln-transformation was carried out for supine
values of LF-HRV, HF-HRV, Total Power-HRV, LF/HF
ratio and LF-SBP. Square root transformation was
carried out for 20° head-up tilt values of LF-HRV,
HF-HRV and Total Power-HRV. Genotype frequency
among patients and healthy controls were explored
with chi-square analyses.
SPSS statistical software (SPSS Inc., Chicago, IL, USA)
was applied for all statistical analyses, and all tests were
carried out two-sided. A p-value ≤ 0.05 was considered
statistically significant. Corrections for multiple compar-
isons were not applied.
Results
A total of 176 CFS patients were referred to the study,
of which 151 were eligible for randomization (Fig. 1). A
total of 120 patients were enrolled and started treatment;
60 patients in the clonidine group and 60 patients in the
placebo group. At week 8, there were 5 dropouts in the
clonidine group and 9 dropouts in the placebo group
(Fig. 1). Further baseline demographic and clinical char-
acteristics are given in Table 2.
At week 8, the clonidine group had statistically signifi-
cantly lower plasma norepinephrine (p = 0.05) and urine
norepinephrine/creatinine ratio (p = 0.002) as compared
to the placebo group (Table 3). At supine rest, the cloni-
dine group had higher heart rate variability in the low-
frequency band (LF-HRV, absolute unites) (p = 0.007)
and as well as higher SDNN (p = 0.05) (Table 4). No
other significant differences were observed. In particular,
symptoms of orthostatic intolerance did not change dur-
ing the intervention period.
Urine norepinephrine/creatinine ratio was negatively
related to plasma clonidine concentration (B = −14.5,
p = 0.004). TPRI supine (B = 4.1, p = 0.01), heart rate
variability in the low-frequency band supine (LF-HRV,
absolute unites) (B = 1423, p = 0.02) and HRV-Total
Power supine (B = 4353, p = 0.04) were positively re-
lated to plasma clonidine concentration. No other
dose response-relationships were found.
Subgrouping according to the 1994 CFS case defin-
ition, genotype frequency of the alpha2A receptor SNP
rs1800544 and sex did not reveal any differential re-
sponse to the intervention. Also, the genotype fre-
quency was equal among CFS patients and healthy
controls (p = 0.75).
Discussion
This study shows that clonidine reduces catechol-
amine levels in adolescent CFS. However, the effects
on cardiovascular autonomic control are sparse, and
clonidine does not improve symptoms of orthostatic
intolerance.
Previous studies have documented that adult as well as
adolescent CFS patients are characterized by enhanced
sympathetic and attenuated parasympathetic nervous ac-
tivity [7, 9, 38, 39]. In particular, CFS patients have
increased levels of catecholamines [40, 41] and a sympa-
thetic predominance of cardiovascular autonomic con-
trol possibly due to central alterations [9, 11, 42]. In this
study, clonidine lowered catecholamine levels as ex-
pected. Of note, urine norepinephrine, which is consid-
ered an index of sympathetic nervous activity over time
[43], decreased dose-dependently.
Clonidine had limited impact on standard cardiovascu-
lar variables, both at rest and during orthostatic chal-
lenge. This finding was surprising. In previous studies of
healthy individuals as well as hypertensive patients, clo-
nidine dosages similar to those applied in this study have
been shown to decrease both blood pressures and heart
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Table 2 Background characteristics
Clonidine (n = 60) Placebo (n = 60)
Gender - no. (%)
Male 13 (22) 21 (35)
Female 47 (78) 39 (65)
Age - years, mean ± SD 15.3 ± 1.5 15.5 ± 1.6
BMI - kg/m2, mean ± SD 21.6 ± 4.4 21.5 ± 4.0
Adheres to 1994 CFS case definition - no. (%)
No 14 (24) 15 (26)
Yes 45 (76) 43 (74)
Genotype a – no. (%)
C/C 32 (53) 35 (58)
C/G 25 (42) 19 (32)
G/G 3 (5) 6 (10)
Disease duration - months, median (range) 18 (4 to 72) 18 (5 to 104)
Disease duration – months, mean ± SD 19.4 ± 13.0 23.5 ± 17.0
School absenteism - %, mean ± SD 66 ± 29 64 ± 31
Smokers – more than once a week – no. 1 0
a The alpha2A receptor single nucleotide polymorphism (SNP) rs1800544. C = Cytosine, G = Guanine
Fig. 1 Study flowchart. Study flowchart. A total of 176 adolescents with CFS were assessed for eligibility. Of these, 151 fulfilled randomization criteria,
whereas 120 started treatment. At week 8, 106 participants were still participating in the intervention program, 55 in the clonidine group and 51 in the
placebo group
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rate, and these alterations of hemodynamics were paral-
leled by a decrement of catecholamines [15, 44–47]. Fur-
thermore, in healthy subjects, clonidine also attenuates
indices of cardiovascular sympathetic nervous modula-
tion (such as LF-HRV), both in supine and sitting
positions [44]. In this study, there was a clonidine-
mediated increase in LF-HRV at supine rest, as well as a
positive relationship between LF-HRV and clonidine
plasma concentration. The interpretation of LF-HRV-
indices is not straight forward; these results, however,
Table 3 Outcome of clonidine intervention – symptom scores and catecholamines
Baseline Week 8 (during treatment)
Symptoms scores
Orthostatic symptoms – total score
Clonidine group, mean 3.8 3.5
Placebo group, mean 3.5 3.5
Difference (95 % CI) −0.05 (−0.5 to 0.4)
p-value (clonidine vs. placebo) 0.84
Palpitations - score
Clonidine group, mean 2.4 2.2
Placebo group, mean 2.2 2.2
Difference (95 % CI) 0.06 (−0.3 to 0.4)
p-value (clonidine vs. placebo) 0.73
Pale and cold hands - score
Clonidine group, mean 3.0 2.7
Placebo group, mean 3.0 2.8
Difference (95 % CI) −0.1 (−0.5 to 0.3)
p-value (clonidine vs. placebo) 0.62
Catecholamines
Plasma norepinephrine - pmol/L
Clonidine group, mean 2040 1557
Placebo group, mean 1942 1761
Difference (95 % CI) −205 (−406 to −4)
p-value (clonidine vs. placebo) 0.05
Plasma epinephrine - pmol/L
Clonidine group, mean 327 291
Placebo group, mean 415 299
Difference (95 % CI) −8 (−44 to 29)
p-value (clonidine vs. placebo) 0.68
Urine norepinephrine/creatinine ratio - nmol/mmol
Clonidine group, mean 13.3 9.6
Placebo group, mean 13.7 13.6
Difference (95 % CI) −3.9 (−6.4 to −1.5)
p-value (clonidine vs. placebo) 0.002
Urine epinephrine/creatinine ratio - nmol/mmol
Clonidine group, mean 1.7 1.2
Placebo group, mean 1.6 1.6
Difference (95 % CI) −0.4 (−0.8 to 0.1)
p-value (clonidine vs. placebo) 0.11
Missing values were imputed based on the principle of last observation carried forwards. Thus, all calculations are based on 120 individuals (60 in each
intervention group except one to two in each group with missing values at baseline). Means and differences at week 8 are estimated from the parameters of the
general linear model
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Table 4 Outcome of clonidine intervention – cardiovascular
variables
Baseline Week 8 (during treatment)
Supine
Heart rate - beats/min
Clonidine group, mean 70 67
Placebo group, mean 72 69
Difference (95 % CI) −2.0 (−4.1 to 0.1)
p-value (clonidine vs. placebo) 0.06
SBP – mmHg
Clonidine group, mean 103 104
Placebo group, mean 107 103
Difference (95 % CI) 1.4 (−1.0 to 3.9)
p-value (clonidine vs. placebo) 0.25
MBP – mmHg
Clonidine group, mean 77 78
Placebo group, mean 80 77
Difference (95 % CI) 1.3 (−0.7 to 3.4)
p-value (clonidine vs. placebo) 0.19
DBP – mmHg
Clonidine group, mean 65 64
Placebo group, mean 66 63
Difference (95 % CI) 0.8 (−1.0 to 2.7)
p-value (clonidine vs. placebo) 0.37
SI - ml/m2
Clonidine group, mean 47 46
Placebo group, mean 46 46
Difference (95 % CI) 0.2 (−2.1 to 2.4)
p-value (clonidine vs. placebo) 0.86
TPRI - mmHg/L/min/m2
Clonidine group, mean 9.1 9.4
Placebo group, mean 8.9 8.9
Difference (95 % CI) 0.5 (−0.1 to 1.1)
p-value (clonidine vs. placebo) 0.11
SDNN – ms
Clonidine group, mean 74 78
Placebo group, mean 66 66
Difference (95 % CI) 12.0 (−0.2 to 23.7)
p-value (clonidine vs. placebo) 0.05
r-MSSD – ms
Clonidine group, mean 79 83
Placebo group, mean 65 70
Difference (95 % CI) 13.1 (−3.2 to 29.5)
p-value (clonidine vs. placebo) 0.11
pNN50 - %
Clonidine group, mean 40 40
Table 4 Outcome of clonidine intervention – cardiovascular
variables (Continued)
Placebo group, mean 31 38
Difference (95 % CI) 2.2 (−3.0 to 7.3)
p-value (clonidine vs. placebo) 0.40
LF-HRV – nu
Clonidine group, mean 40 42
Placebo group, mean 43 38
Difference (95 % CI) 3.7 (−0.5 to 8.0)
p-value (clonidine vs. placebo) 0.08
HF-HRV – nu
Clonidine group, mean 60 58
Placebo group, mean 57 62
Difference (95 % CI) −3.7 (−8.0 to 0.5)
p-value (clonidine vs. placebo) 0.08
LF-HRV* - ms2
Clonidine group, mean 628 679
Placebo group, mean 451 487
Ratio (95 % CI) 1.4 (1.1 to 1.8)
p-value (clonidine vs. placebo) 0.007
HF-HRV* - ms2
Clonidine group, mean 962 961
Placebo group, mean 600 825
Ratio (95 % CI) 1.2 (0.9 to 1.5)
p-value (clonidine vs. placebo) 0.28
Total Power-HRV* - ms2
Clonidine group, mean 1991 2053
Placebo group, mean 1352 1638
Ratio (95 % CI) 1.3 (1.0 to 1.6)
p-value (clonidine vs. placebo) 0.06
LF/HF-ratio*
Clonidine group, mean 0.65 0.70
Placebo group, mean 0.75 0.59
Ratio (95 % CI) 1.2 (1.0 to 1.4)
p-value (clonidine vs. placebo) 0.09
LF-SBP – nu
Clonidine group, mean 39.3 38.0
Placebo group, mean 38.1 36.9
Difference (95 % CI) 1.1 (−3.0 to 5.2)
p-value (clonidine vs. placebo) 0.60
LF-SBP* - mmHgs2
Clonidine group, mean 3.8 3.7
Placebo group, mean 3.0 3.2
Ratio (95 % CI) 1.1 (0.9 to 1.5)
p-value (clonidine vs. placebo) 0.34
Response to 20° head-up tilt
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Table 4 Outcome of clonidine intervention – cardiovascular
variables (Continued)
Heart rate - beats/min
Clonidine group, mean 5.2 4.9
Placebo group, mean 4.8 4.9
Difference (95 % CI) 0.0 (−1.1 to 1.2)
p-value (clonidine vs. placebo) 0.97
SBP – mmHg
Clonidine group, mean 0.74 −0.59
Placebo group, mean 0.15 −0.01
Difference (95 % CI) −0.58 (−2.2 to 1.0)
p-value (clonidine vs. placebo) 0.48
MBP - mmHg
Clonidine group, mean 1.19 0.61
Placebo group, mean 0.94 1.23
Difference (95 % CI) −0.63 (−2.1 to 0.8)
p-value (clonidine vs. placebo) 0.39
DBP - mmHg
Clonidine group, mean 1.13 1.2
Placebo group, mean 1.58 1.8
Difference (95 % CI) −0.59 (−2.0 to 0.8)
p-value (clonidine vs. placebo) 0.40
SI - ml/m2
Clonidine group, mean −5.9 −4.5
Placebo group, mean −5.1 −5.3
Difference (95 % CI) 0.9 (−0.4 to 2.1)
p-value (clonidine vs. placebo) 0.17
TPRI - mmHg/L/min/m2
Clonidine group, mean 0.66 0.44
Placebo group, mean 0.60 0.62
Difference (95 % CI) −0.18 (−0.47 to 0.11)
p-value (clonidine vs. placebo) 0.22
SDNN - ms
Clonidine group, mean −5.1 −7.9
Placebo group, mean −4.4 −0.7
Difference (95 % CI) −7.2 (−16.0 to 1.6)
p-value (clonidine vs. placebo) 0.11
r-MSSD - ms
Clonidine group, mean −18 −24
Placebo group, mean −16 −17
Difference (95 % CI) −7.6 (−19.6 to 4.4)
p-value (clonidine vs. placebo) 0.11
pNN50 - %
Clonidine group, mean −14 −11
Placebo group, mean −9 −13
Difference (95 % CI) 1.2 (−3.1 to 5.4)
Table 4 Outcome of clonidine intervention – cardiovascular
variables (Continued)
p-value (clonidine vs. placebo) 0.59
LF-HRV - nu
Clonidine group, mean 8.3 6.1
Placebo group, mean 6.7 9.2
Difference (95 % CI) −3.1 (−7.4 to 1.1)
p-value (clonidine vs. placebo) 0.15
HF-HRV - nu
Clonidine group, mean −8.3 −6.1
Placebo group, mean −6.7 −9.2
Difference (95 % CI) 3.1 (−1.1 to 7.4)
p-value (clonidine vs. placebo) 0.15
LF-HRV# - ms2
Clonidine group, mean −320 −161
Placebo group, mean −176 −171
n.a. n.a.
p-value (clonidine vs. placebo) 0.87
HF-HRV# - ms2
Clonidine group, mean −828 −640
Placebo group, mean −523 −629
n.a. n.a.
p-value (clonidine vs. placebo) 0.99
Total Power-HRV# - ms2
Clonidine group, mean −1107 −790
Placebo group, mean −668 −736
n.a. n.a.
p-value (clonidine vs. placebo) 0.78
LF/HF-ratio
Clonidine group, mean 0.35 0.34
Placebo group, mean 0.44 0.55
Difference (95 % CI) −0.21 (−0.46 to 0.04)
p-value (clonidine vs. placebo) 0.09
LF-SBP - nu
Clonidine group, mean 2.5 4.4
Placebo group, mean 3.2 3.7
Difference (95 % CI) 0.7 (−2.4 to 3.8)
p-value (clonidine vs. placebo) 0.66
LF-SBP - mmHgs2
Clonidine group, mean −2.6 −1.0
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might suggest an enhancement of sympathetic heart
rate modulation, resembling the effects of clonidine in
essential hypertension [48]. This is in contrast to ef-
fects of clonidine in healthy subjects [44]. A previous
study suggests early sympathetic baroreceptor activa-
tion and diminished baroreceptor reserve in CFS [11].
We speculate that clonidine, by way of reducing sympa-
thetic tone (as evident from the catecholamine-lowering
effect), might in fact increase the sympathetic nervous sys-
tem modulatory effects [49].
Taken together, the findings presented in this study
suggest an alteration of clonidine pharmacodynamics in
CFS. One possible explanation is genetically determined
differences of the alpha2A receptor protein, which is the
ligand for clonidine. A single nucleotide polymorphism
(SNP) (rs1800544) in the alpha2A receptor gene implies
substitution of guanine (G) for cytosine (C) at position
1291, and has functional consequences [18]. However, the
genotype frequencies among CFS patients and a compar-
able group of healthy controls were almost identical, and
subgroup analysis based on genotype revealed no differ-
ences in response to treatment. Another possible explan-
ation is altered expression of adrenoceptors, as has
previously been demonstrated in CFS [50] as well as in
other conditions with high levels of catecholamines [51].
The possibility of increased long-term cardiovascular
risk in CFS patients remains a concern [52]. In addition
to increased sympathetic nervous activity, CFS patients
are also characterized by slight inflammatory activation
[28] and elevated nocturnal blood pressure and heart
rate [53], which in turn are associated with development
of atherosclerosis. Further research is warranted to clar-
ify the eventual need of prophylactic measures.
A possible limitation of this study is the wide inclusion
criteria and no a priori-definition of the degree of school
absenteeism necessary to fulfil the diagnostic criteria,
which might have obscured results applying to a sub-
group only. However, the study population corresponds
closely to the population who is diagnosed as CFS by pe-
diatricians; thus, we assume the external validity to be
strong. Furthermore, subgrouping based upon the 1994
CFS case definition did not change the results. We have
not done subgrouping based on caffeine use. Another
limitation of this study is the 4 min epochs used for
time-domain analyses of heart rate variability, as op-
posed to the 5 min epochs recommended [32]. It is con-
sidered inappropriate to compare time-domain indices
(especially SDNN) obtained from recordings of different
durations; while the present study does not violate this
principle, caution should be shown when comparing our
results to other studies. Strengths of this study include
high compliance and low drop-out-rates, and the suc-
cessful blinding of all (staff and patients) clinically in-
volved in the study.
Conclusions
Low-dose clonidine reduces catecholamine levels in ado-
lescent CFS. However, the effects on cardiovascular
autonomic control are sparse, and clonidine does not
improve symptoms of orthostatic intolerance.
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